GlobeNewswire: Zogenix Contains the last 10 of 148 releaseshttp://www.globenewswire.com/External?Length=42024-03-19T08:27:14ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2015/03/26/719153/10126427/en/Zogenix-Announces-First-Patient-Dosed-in-Relday-Multi-Dose-Clinical-Study.html?f=22&fvtc=4&fvtv=12759Zogenix Announces First Patient Dosed in Relday Multi-Dose Clinical Study2015-03-26T13:00:00Z<![CDATA[Results Anticipated in Third Quarter 2015, Positioning Zogenix for Potential World-Wide Partnering Opportunities for Relday SAN DIEGO, March 26, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders, announced today that dosing has begun in patients enrolled in its Relday™ multi-dose Phase 1b clinical study. Relday is a proprietary, long-acting, subcutaneously injected formulation of risperidone being investigated for the treatment of schizophrenia.]]>https://www.globenewswire.com/news-release/2015/03/10/714074/10124115/en/Zogenix-Announces-Agreement-of-Sale-of-Zohydro-R-ER-Business-to-Pernix-for-100-Million-at-Closing-Plus-Potential-Milestones-of-283-5-Million.html?f=22&fvtc=4&fvtv=12759Zogenix Announces Agreement of Sale of Zohydro(R) ER Business to Pernix for $100 Million at Closing Plus Potential Milestones of $283.5 Million2015-03-10T20:05:00Z<![CDATA[Enables planned implementation of new strategic focus to developing a late-stage, high-value CNS pipeline]]>https://www.globenewswire.com/news-release/2015/03/10/714078/10124130/en/Zogenix-Reports-Fourth-Quarter-and-Full-Year-2014-Financial-Results.html?f=22&fvtc=4&fvtv=12759Zogenix Reports Fourth Quarter and Full Year 2014 Financial Results2015-03-10T20:05:00Z<![CDATA[Conference Call and Webcast to Discuss Fourth Quarter Results and Definitive Agreement to Sell Zohydro ER to Pernix; Scheduled for Today, March 10, at 4:30 p.m. ET Clinical and Regulatory Update]]>https://www.globenewswire.com/news-release/2015/03/02/711577/10122785/en/Zogenix-Announces-Conference-Call-and-Webcast-to-Present-Fourth-Quarter-and-Full-Year-2014-Financial-Results.html?f=22&fvtc=4&fvtv=12759Zogenix Announces Conference Call and Webcast to Present Fourth Quarter and Full Year 2014 Financial Results2015-03-02T21:05:00Z<![CDATA[Conference Call Scheduled for March 10, 2015 at 4:30 pm ET SAN DIEGO, March 2, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders, today announced it will release financial results for the fourth quarter and full year ended December 31, 2014, after the market closes on Tuesday, March 10, 2015, and will hold a conference call on this day at 4:30 p.m. ET (1:30 p.m. PT), to discuss these financial results and provide a company update.]]>https://www.globenewswire.com/news-release/2015/02/10/705058/10119590/en/Zogenix-Appoints-Industry-Veteran-Renee-Tannenbaum-to-Its-Board-of-Directors.html?f=22&fvtc=4&fvtv=12759Zogenix Appoints Industry Veteran Renee Tannenbaum to Its Board of Directors2015-02-10T21:01:00Z<![CDATA[SAN DIEGO, Feb. 10, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders, announced today that Renee Tannenbaum, Pharm.D., has been appointed as a new member of the Company's Board of Directors.]]>https://www.globenewswire.com/news-release/2015/02/05/703597/10118822/en/Zogenix-to-Participate-in-Leerink-Global-Healthcare-Conference.html?f=22&fvtc=4&fvtv=12759Zogenix to Participate in Leerink Global Healthcare Conference2015-02-05T14:00:00Z<![CDATA[SAN DIEGO, Feb. 5, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders, today announced that Ann Rhoads, Chief Financial Officer, will present at the Leerink Global Healthcare Conference in New York, NY on February 11, 2015. Ms. Rhoads will participate in a fireside chat presentation and provide a general company update.]]>https://www.globenewswire.com/news-release/2015/01/31/701783/10117925/en/Zogenix-Receives-FDA-Approval-of-New-Formulation-of-Zohydro-R-ER.html?f=22&fvtc=4&fvtv=12759Zogenix Receives FDA Approval of New Formulation of Zohydro(R) ER2015-01-31T00:05:00Z<![CDATA[Zohydro ER With BeadTek(TM) to be Available in the Second Quarter of 2015 SAN DIEGO, Jan. 30, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has approved a new formulation of Zohydro]]>https://www.globenewswire.com/news-release/2015/01/12/696635/10115006/en/Zogenix-Provides-Business-Update.html?f=22&fvtc=4&fvtv=12759Zogenix Provides Business Update2015-01-12T12:30:00Z<![CDATA[SAN DIEGO, Jan. 12, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central nervous system (CNS) disorders, announced today a business update including recent company highlights, the most recent Zohydro ER prescription trends and the Company's year-end 2014 cash position.]]>https://www.globenewswire.com/news-release/2014/12/03/688511/10110907/en/Zogenix-to-Participate-in-Oppenheimer-25th-Annual-Healthcare-Conference.html?f=22&fvtc=4&fvtv=12759Zogenix to Participate in Oppenheimer 25th Annual Healthcare Conference2014-12-03T21:30:00Z<![CDATA[SAN DIEGO, Dec. 3, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central nervous system disorders, today announced that Stephen Farr, President, and Ann Rhoads, Chief Financial Officer, will present at the Oppenheimer 25]]>https://www.globenewswire.com/news-release/2014/12/01/687534/10110133/en/Results-of-Long-Term-Open-Label-Study-Published-in-the-Journal-of-Pain-Research-Demonstrate-the-Safety-Tolerability-and-Effectiveness-of-Zohydro-R-ER.html?f=22&fvtc=4&fvtv=12759Results of Long-Term, Open-Label Study Published in the Journal of Pain Research Demonstrate the Safety, Tolerability and Effectiveness of Zohydro(R) ER2014-12-01T13:30:00Z<![CDATA[Findings Contribute to Growing Body of Evidence Supporting Efficacy and Safety Profile SAN DIEGO, Dec. 1, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, today announced the publication of a long-term Phase 3 open-label study, which showed that Zohydro]]>